Anti-Human BCMA/TNFRSF17 Reference Antibody (Ispectamab, RUO)
- Catalog number: BS10815
- Availability: In Stock
$326.00
- Ex Tax: $326.00
Description: Ispectamab (BS10815) is a research-grade recombinant antibody targeting CD269. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Tumornecrosisfactorreceptorsuperfamilymember17,TNFRSF17,CD269,B-cellmaturationprotein,BCMA,BCM
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BMS-986352,CC-99712,CC99712,CC99712,SP8919,CAS:2413386-21-5
Background: Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli).
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: Tumornecrosisfactorreceptorsuperfamilymember17,TNFRSF17,CD269,B-cellmaturationprotein,BCMA,BCM
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: BMS-986352,CC-99712,CC99712,CC99712,SP8919,CAS:2413386-21-5
Background: Tumor necrosis factor receptor superfamily member 17 (CD269/BCMA) is a ~20 kDa protein. Receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. Promotes B-cell survival and plays a role in the regulation of humoral immunity. Activates NF-kappa-B and JNK. CD269 is the therapeutic target of teclistamab (Tecvayli).
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
Western blotWestern blot analysis was performed using anti-CD269 monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human CD269 (Catalog No: PH15966)
Lane 2: negative control -
SDS-PAGESDS-PAGE for Research Grade Ispectamab.
-
BioactivityDetects recombinant human CD269/TNFRSF17/BCMA (Catalog No: PH15966) in indirect ELISA
